

MGM1434 : POLE gene sequencing

Report Details	Specimen Information	Ordering Clinician
Sample ID / Order ID: 9589960 / 1542532	Specimen Site: Endometrium	Clinician: Dr. Mahilal Wijekoon
Collection Date: 22 nd November 2025	Specimen Received: FFPE Tissue Blocks [3]	Affiliation: Aegle Omics Private Limited
Date Received: 1 st December 2025	Specimen Tested: GR2714 H	Serviced By: 18718
Report Date & Time: 16 th Dec 2025 18:06 PM	Tumor Content (%): 30	Report Status: Final

Clinical Summary:
Endometrioid endometrial carcinoma: FIGO grade 1, stage IB; pT1a. p53 negative

TEST RESULT SUMMARY

Next Generation Sequencing (NGS) Results	
NEGATIVE	
Gene	Findings
POLE	Not Detected

Next Generation Sequencing (NGS) Test Result

Result - NEGATIVE				
NO CLINICALLY RELEVANT VARIANT/S DETECTED				
AMP Classification ^	CDS variant details	Interpretation	Treatment Recommendations	\$Treatment Response
No clinically significant variants detected				

^ Refer to Glossary section for the classification criteria details.

\$ Drug Approvals are based on US-FDA Guidelines. Kindly refer to local guidelines if required.

ADDITIONAL BIOMARKERS DETECTED

This section provides information about variants that do not have any therapeutic value. However, these variants may or may not have a likely oncogenic effect.

AMP-ASCO-CAP CLASSIFICATION CRITERIA

Genetic test results are reported based on the somatic variant classification recommendations of College of American Pathologists (CAP) /American society for Clinical Oncology (ASCO)/Association of Molecular Pathologists (AMP) [PMID: 27993330] as described in the table below:

Tier	Criteria
Tier I	Variants of strong clinical significance.
Tier II	Variants of potential clinical significance.
Tier III	Variants of unknown clinical significance
Tier IV	Benign or likely benign variants

DISCLAIMER

- **Decisions regarding treatment action plan should not be solely based on these test results. These findings are highly recommended to be correlated with the patient's clinical, pathological, radiological and family history for decisions on diagnosis, prognosis, or therapeutics.**
- The therapy information provided in this report is based on FDA approved drugs data, NCCN guidelines, peer-reviewed published literature, standard clinical databases, and strength of biomarker results. These therapies may or may not be suitable/beneficial to a particular patient. This clinical report summarizes potentially effective medications, potentially ineffective medications, and medications that may pose a higher risk of adverse reactions by mapping the patient's genetic alterations to the biomedical reference information. The report may also provide prognostic and diagnostic biomarkers detected or shown for the given disease context.
- The clinical trials information provided in this report is compiled from www.clinicaltrials.gov as per currently available data, however completeness of information provided herein cannot be guaranteed. This information should only be used as a guide and specific eligibility criteria should be reviewed thoroughly for the concerned patient. MedGenome Labs does not guarantee or promise an enrolment in any clinical trials.
- The identification of a genomic biomarker does not necessarily imply pharmacological effectiveness or ineffectiveness. The medications identified by the treating physician may or may not be suitable for use on a particular patient. Thus, the clinical report does not guarantee that any particular agent will be effective in the treatment of any particular condition. Also, the absence of a treatment option does not determine the effectiveness or predict an ineffective or safety-relevant effect of a medication selected by the treating physician.
- The classification and clinically relevant information for the reported variants is based on peer-reviewed publications, public clinical databases, medical guidelines (WHO, NCCN, ASCO, AMP) or other publicly available information and it has been ensured that the information provided is up to date at the time of report generated, however continuous updates may happen in public domains. Also, the classification of variants can change based on the updated literature evidence. Re-analysis of the results can be requested at additional cost.
- This test is performed on the patient's tumor sample without a paired blood sample; therefore, it may include variations which may be of germline origin. However, this test is designed and validated for the detection and reporting of somatic genomic variants only and does not discriminate between germline and somatic variants. If clinically warranted, appropriate germline testing and genetic counselling for the patient should be considered for further evaluation.
- **Due to poor quality of FFPE tissue blocks, the QC parameters for extracted DNA may not pass to proceed further with the testing, therefore there is a possibility of assay failure at various steps (DNA QC, Library QC, Bioinformatics QC) or compromised results that include low gene coverage and low variant depth.** However, sample status in such scenarios shall be sent through mail to the ordering clinician.

- This test has been validated at MedGenome Labs and the limit of detection (LOD) of allele fraction for SNVs and InDels is $\geq 5\%$. However, the report may include, at the discretion of laboratory director, the variants with lower allele burden (3-5%) having strong or potential clinical significance or those have been reported earlier in the patient. Variants with $< 1\%$ allele fraction and variants of uncertain significance with $< 5\%$ allele fraction are not routinely reported. However, possibility of false negative or false positive below the limit of detection of this assay cannot be ruled out.
- Large deletions and deep intronic variations are not detected in this assay.
- Additional case specific disclaimer : None

TEST DESCRIPTION

POLE gene mutation analysis by NGS is a high throughput next-generation sequencing assay that covers complete coding regions of the *POLE* gene associated with tumorigenesis, prognostication and predictive therapeutics in different tumor types.

TEST METHODOLOGY

Sample Type: FFPE Specimen; A histopathologic review is performed to determine the tumor content in the FFPE block/curls.

Extraction and Library Preparation: Tumor DNA is extracted from FFPE (Formalin fixed) tissue block and used to perform targeted gene capture and sequencing.

Sequencing: The QC passed libraries are sequenced to a minimum depth of 250X on validated Illumina sequencing platform.

Data Analysis: The sequences are processed using a customized and validated analysis pipeline designed to accurately detect all classes of genomic alterations (SNVs and InDels).

Variant Annotation and Reporting: The variants are annotated using our in-house annotation pipeline. Reportable genomic alterations are prioritized, classified, and reported based on AMP-ASCO-CAP guidelines [PMID: [27993330](https://pubmed.ncbi.nlm.nih.gov/27993330/)] and NCCN guidelines.

Limit of Detection (LOD): The LOD for SNVs and InDels is 5% Variant allele Frequency (VAF).

The transcript used for clinical reporting generally represents the canonical transcript (according to Ensembl release 99 human gene model), which is usually the longest coding transcript with strong/multiple supporting evidence. However, clinically relevant variants annotated in alternate complete coding transcripts could also be reported. Variants annotated on incomplete, and nonsense mediated decay transcripts are not reported.

§This test is developed, and its performance characteristics is determined by MedGenome Labs Ltd.

GENES ANALYSED

SNVs/InDels

POLE

CLINICAL TRIALS

The following trials are potentially best suited for your patient's indication, considering all reported treatment recommendations. See <https://clinicaltrials.gov> (clinical trials from NCT) or <https://trialsearch.who.int> (clinical trials from other registries) for more information.

Clinical trials in total : 0 Trial countries : IN-India, US-United States

S.No	Title	Phase and ID	Intervention	Disease	Age & Sex
No Clinical Trials.					

N. Aparna

Aparna Natarajan, Ph.D
Lead - Genome Analyst (Oncology)

Dr. Syed Muqlisur Rehman

Dr. Syed Muqlisur Rehman, MD Path
Molecular Pathologist
KMC Registration No. 71468

END OF REPORT